Attorney's Docket No.: 06273-517US1/101307-1P US

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nafizal Hossain et al. Art Unit : Unknown Serial No. : 10/583,468 Examiner: Unknown

Filed : June 20, 2006 Conf. No.: 1675

: NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF Title

CHEMOKINE RECEPTOR ACTIVITY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Please correct the Filing Receipt for the above-referenced application to reflect the correct spelling of the title NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. The error was made by the U.S. Patent and Trademark Office as evidenced by the Transmittal Letter and Combined Declaration and Power of Attorney (copies enclosed).

Please supply a corrected Filing Receipt to the undersigned with respect to this application. A copy of the original Filing Receipt showing the desired change is attached for your convenience.

No fee is believed to be due. If, however, there are any charges or credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Reg. No. 34,819

for Janis K. Fraser, Ph.D., J.D.

Fish & Richardson P.C.

225 Franklin Street Boston, MA 02110

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21579963.doc



ATTORNEY'S D	XXKET NUMBER
06275-517US1	101307-1P US

	RANSMITTAL LETTER TO DESIGNATED/ELECTED ( ONCERNING A SUBMISSIO	OFFICE (DO/EO/US) N UNDER 35 U.S.C. 371	ATTORNEY'S DOCKET NUMBER  06275-517US1   101307-1P US  U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIM 20 December 2004 22 December 2003		PRIORITY DATE CLAIMED 22 December 2003	
TITLE C	of INVENTION Tricyclic Spiroderivatives as Modulators	of Chemokine Receptor Activity	
	ANT(S) FOR DO/EO/US Hossain and Svetlana Ivanova		
Applics  1.   2.	This is a FIRST submission of items c	onceming a submission under 35 U.S.C	
<ol> <li>This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</li> <li>This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> </ol>			
4. 🗆	4. The US has been sleeted (Article 31).		
5. 🏻	<ul> <li>a.  is attached hereto (required of the communicated by t</li></ul>	nly if not communicated by the Interna he International Bureau. nion was filed in the United States Reco	civing Office (RO/US).
			v er 25 1595 ( . ) ( 5) \

<b>4</b> .		The US has been elected (Article 31).		
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a.   is attached hereto (required only if not communicated by the International Bureau).  b.   has been communicated by the International Bureau.  c.   is not required, as the application was filed in the United States Receiving Office (RO/US).		
ő.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).		
7.	Ø	a.		
8.		An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
	Iten	ns 11 to 28 below concern document(s) or information included:		
11.	$\boxtimes$	An Information Disclosure Statemens under 37 C.F.R. 1.97 and 1.98.		
12.	Ø	An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.		
13:	$\boxtimes$	A preliminary amendment.		
14.		An Application Data Sheet under 37 C.F.R. 1.76.		
15.		A substitute specification.		
16.		A power of attorney and/or change of address letter.		
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825.		
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).		

19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

CERTIFICATE OF MAILING BY EXPRESS MAIL Express Mail Label No. EL 980876535 US June 29, 2096 Date of Deposit:

Substitute	27 Ourson
-33330000 X 3 C X 4 A C V	2 2 (2.233.0)

ASSESSED DE CONTRACTOR DE CONT	***************************************		
s. 🛭	A check in the amount of \$940.00 to cover the above fees is enclosed.		
b. 🗆	Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.		
e. 🔯	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.		
d. 🖂	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
NOTE: Where an appropriate time limit under 37 C.F.R. 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b) must be filed and granted to restore the International Application to pending status.			
SEND A	LL CORRESPONDENCE TO:	arrei:	SIGNATURE M. M. M. Carte Paga Mr. 54.301
	PTO Customer No:	26164	Janis K. Fraser, Ph.D., J.D.
			NAME
			34,8{9
			REGISTRATION NUMBER

21359954.doc

101307-1P US

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

# NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

the spe	cification of which:		
	is attached hereto.		
OR	was filed on	with Express Mail No.	(Application Number not yet known).
OR	PCT International Applica	ember 2004 as United Stat ation Number <u>PCT/SE2004/001938</u> (if applicable).	es Application Number or and was amended on
includi		reviewed and understand the contents on y any amendment referred to above.	f the above-identified specification,
§1.56.	I acknowledge the duty to	disclose information which is material	to patentability as defined in 37 CFR
applica	I hereby claim the benefit ation(s) listed below:	under Title 35, United States Code, §1	19(e)(1) of any United States provisional
	U.S. Serial No.	Filing Date	Status
matter international acknown of Federation	) of any PCT international a of each of the claims of this ational application in the man vedge the duty to disclose a	application designating the United State application is not disclosed in the prior nner provided by the first paragraph of all information I know to be material to thich became available between the filit	Title 35, United States Code, §112, I patentability as defined in Title 37, Code
	U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Sweden	0303541-7	22 December 2003	⊠Yes □No
			Yes No

I hereby appoint all registered practitioners associated with Customer Number 26164 to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

#### Customer Number 26164

Direct all telephone calls to JANIS K. FRASER, Ph.D., J.D., Reg. No. 34,819, at telephone number (617) 542-5070.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Nafizal HOSSAIN Full Name of inventor:

Natizal Hoserai Date: 2006-05-05 Lund, Sweden Residence Address:

SE Citizenship:

inventor's Signature:

AstraZeneca R&D Lund, SE-221 87 Lund, Sweden Post Office Address:

Full Name of Inventor: Svetlana IVANOVA
Inventor's Signature: Date: 2006-05-05
Residence Address: Lund, Sweden
Citizenship: RU

Post Office Address: AstraZeneca R&D Lund, SE-221 87 Lund, Sweden



3 11 11

Š

### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Potent and Trademark Office Address COMMISSIONER FOR PAYENTS OF SECTION

COMMONSON CONTROL CONTROL 2005 80 ISSN 1450 Alexandra, Vagoria, 22532-1450 www.imple.gov.

APPLINO. FILING OR 371 ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS INDICLMS 10/583,468 06/20/2006 1614 900 06275-517US1 101307-1P US 20 1

**CONFIRMATION NO. 1675** 

FILING RECEIPT

\*OC000000022163105\*

26164 FISH & RICHARDSON P.C. P.O BOX 1022 MINNEAPOLIS, MN 55440-1022

Date Mailed: 01/26/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Nafizal Hossain, Lund, SWEDEN; Svetlana Ivanova, Lund, SWEDEN;

Power of Attorney: The patent practitioners associated with Customer Number 26164.

#### Domestic Priority data as claimed by applicant

This application is a 371 of PCT/SE04/01938 12/20/2004

#### Foreign Applications

SWEDEN 0303541-7 12/22/2003

If Required, Foreign Filing License Granted: 01/25/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/583.468

Projected Publication Date: 05/03/2007

Non-Publication Request: No

Early Publication Request: No

Title

activity

Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity-

**Preliminary Class** 

514

#### PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof

unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).